Oggolaanshaha oggolaanshaha Kalsiyum Rosuvastatin

Dhawaan, Nantong Chanyoo waxay sameeyeen taariikh kale oo taariikhi ah! Dadaalka in kabadan hal sano, KDMF-tii ugu horeysay ee Chanyoo waxaa ogolaaday MFDS. Maadaama aan nahay soo saaraha ugu weyn ee Rosuvastatin Calcium dalka Shiinaha, waxaan jeclaan lahayn inaan u furno bog cusub suuqa Korea. Iyo badeecooyin badan ayaa la bilaabi doonaa sanadaha soo socda.

Sidoo kale, waad gudbin kartaa oo ka heli kartaa macluumaadkeena degelkan:

https://nedrug.mfds.go.kr/pbp/CCBAC03

Kalsiyum Rosuvastatin wuxuu ku habboon yahay daaweynta ku-habboon ee bukaanka qaba cudurka 'hypercholesterolemia' (nooca IIa, oo ay ku jiraan heterozygous familial hypercholesterolemia) ama lipopia isku qasan (nooca IIb) marka cunno qaadashada ama daaweynta jimicsiga aysan fiicnayn. Kalsiyum Rosuvastatin waa xulasho 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) inhibctase inhibitor. Iyadoo la joojinayo HMG-CoA reductase, waxay yareysaa isku-darka unugyada beerka iyo keydinta kolestaroolka, sidaasna waxay hoos u dhigeysaa wadarta kolestaroolka (TC) iyo heerarka hoose ee lipoprotein kolestaroolka (LDL-C).

Sida laga soo xigtay xogta Newport, laga bilaabo Juun 30, 2018 illaa Juun 30, 2019, iibka adduunka ee diyaarinta kalsiyum rosuvastatin wuxuu ahaa US $ 3.461 bilyan, hoos u dhac sanad-sannadeedka ah 13%; iibka caalamiga ah ee alaabta ceyriinka rosuvastatin ee kalsiyum waxay ahaayeen 151.09 tan, Kordhin sanadle ah oo 14% ah

Annaga, Changzhou Pharmaceutical Factory (soo saaraha hoosaad: Nantong Chanyoo Pharmatech Co., Ltd.) waxaan u go'nay shirkad-soo-saaraha ugu weyn ee Rosuvastatin API.

newsg


Waqtiga boostada: Abriil-20-2021